Hyperbaric oxygen and UVB light for vitiligo
Part of Skin clinical trials.
This study tests whether combining hyperbaric oxygen (breathing pure oxygen in a special chamber) with narrowband UVB light therapy can improve vitiligo, a condition that causes white patches on the skin. The treatment aims to restore skin color by helping skin cells produce pigment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-segmental vitiligo for at least 3 months.
- Vitiligo patches cover between 4% and 60% of your body, not counting your palms, soles of feet, or top of feet.
- You have some vitiligo on your face (at least 0.5% of your face is affected).
- Your vitiligo is active and stable, and you have not had more than a third of your patches turn completely white with no pigment.
- If you are a woman who can have children, you must use effective birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a type of light therapy (narrow-band UVB) to a daily pill called ritlecitinib works better than the pill alone for treating vitiligo. It may help if you have non-segmental vitiligo covering a moderate amount of skin.
This trial tests a new treatment for non-segmental vitiligo that uses a special liquid made from stem cells, applied through tiny needle pricks or small injections, alongside standard light therapy. It may help restore pigment to white patches with fewer side effects than traditional treatments.
This study tests a combination of microneedling, a topical solution called minoxidil, and narrowband UVB light therapy to see if it can improve stable vitiligo patches. It may help repigment the skin where color has been lost.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This trial tests a new treatment for people with active generalized vitiligo covering more than 5% of their body (not counting hands and feet). It also looks at a protein in the blood called s100B to see how it relates to the condition and treatment response.
This trial tests whether adding a daily nasal spray (Melanotan II) to light therapy helps restore color in stable vitiligo patches. It may be a good option for adults with mild to moderate nonsegmental vitiligo that hasn't changed in at least 6 months.
Hear when a new Vitiligo Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.